Recombinant Human Granulocyte Stimulating Factor Injection has the effect of stimulating the proliferation of bone marrow granulocytes, and can be used for the prevention and treatment of neutropenia caused by cancer chemotherapy, aplastic anemia, myelodysplastic syndromes, etc., and can also be used to elevate neutrophils after bone marrow transplantation. Adverse reactions such as fever, headache, malaise, myalgia, rash, bone pain, shock, loss of appetite, interstitial pneumonitis, elevated gammaglutaminase, increased naïve cells, and adult respiratory distress syndrome can occur with the use of this drug. When using the drug, blood tests, especially the number of neutrophils, should be checked regularly twice a week. If allergic reactions such as rash, hypotension, facial swelling, tachycardia, dyspnea, etc. occur after the use of the drug, the drug should be immediately discontinued, and antihistamines, bronchial antispasmodics, glucocorticosteroids, adrenaline and other drugs should be used according to the situation. Contraindicated in the following cases: hypersensitivity to the drug or other E. coli preparations; myelogenous leukemia in which naïve granulocytes are detected in the peripheral blood; severe cardiac, pulmonary, hepatic and renal insufficiency; myelogenous leukemia in which naïve granulocytes in the bone marrow have not been significantly reduced. Use with caution in the following cases: patients with acute myelogenous leukemia and other malignant proliferations of the myeloid cell system; children. Pregnant women, women who may become pregnant and lactating women should be carefully considered before using the drug. Nursing women must stop breastfeeding when using the drug. If you need to use the drug, please strictly follow the doctor’s instructions to take the drug, do not self-medication.